New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
10:26 EDTBMO, PAGP, NJR, NGG, MDAS, MANU, AWAY, HSY, FIATY, EDPFY, DG, DLR, DSW, CS, CRZBD, CELG, WOPEYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bank of Montreal (BMO) downgraded to Sector Perform from Outperform at RBC Capital... Celgene (CELG) downgraded to Neutral from Overweight at JPMorgan... Commerzbank (CRZBD) downgraded to Neutral from Outperform at Exane BNP Paribas... Credit Suisse (CS) downgraded to Neutral from Buy at BofA/Merrill... DSW (DSW) downgraded to Neutral from Positive at Susquehanna... Digital Realty (DLR) downgraded to Hold from Buy at Cantor... Dollar General (DG) downgraded at Sterne Agee... Energias de Portugal (EDPFY) downgraded to Sell from Neutral at Citigroup... Fiat (FIATY) downgraded to Underperform from Market Perform at Bernstein... Hershey (HSY) downgraded to Hold from Buy at Argus... HomeAway (AWAY) downgraded to Neutral from Overweight at JPMorgan... Manchester United (MANU) downgraded to Neutral from Overweight at JPMorgan... MedAssets (MDAS) downgraded to Neutral from Buy at Citigroup... National Grid (NGG) downgraded to Neutral from Outperform at Credit Suisse... New Jersey Resources (NJR) downgraded to Hold from Buy at Brean Capital... Plains GP Holdings (PAGP) downgraded to Equal Weight from Overweight at Stephens... Woodside Petroleum (WOPEY) downgraded to Market Perform from Outperform at Bernstei.
News For BMO;CELG;CRZBD;CS;DSW;DLR;DG;EDPFY;FIATY;HSY;AWAY;MANU;MDAS;NGG;NJR;PAGP;WOPEY From The Last 14 Days
Check below for free stories on BMO;CELG;CRZBD;CS;DSW;DLR;DG;EDPFY;FIATY;HSY;AWAY;MANU;MDAS;NGG;NJR;PAGP;WOPEY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 9, 2014
16:25 EDTCELGCelgene reports 11.9% passive stake in GlobeImmune
Subscribe for More Information
11:57 EDTCELGCelgene shares higher despite missing primary endpoint in Otezla trial
Subscribe for More Information
10:48 EDTMANUYOU On Demand rallies after Attiva reports 'small stake'
Shares of YOU On Demand (YOD) are moving higher after Attiva Capital last night tweeted that it has taken a "small stake" in the company. Attiva also said it has a taken a small stake in Manchester United (MANU). Shares of YOU On Demand are up 5%, or 14c, to $2.89 in early trading. Reference Link
10:02 EDTAWAYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:47 EDTFIATYNew car sales in India rose 15% in June, WSJ reports
Subscribe for More Information
09:43 EDTMANUGeneral Motors, Manchester United debut sponsored shirt for 2014-15 season
Subscribe for More Information
09:35 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AA FB AMZN TSLA TWTR MU NFLX GG CELG
09:13 EDTCELGOn The Fly: Pre-market Movers
Subscribe for More Information
07:04 EDTCELGCelgene says OTEZLA did not achieve primary endpoint in Phase III trial
Celgene Corporation announced results of its phase III POSTURE study evaluating OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4, in patients with active ankylosing spondylitis. The OTEZLA arms did not achieve statistically significant improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS 20 response at week 16. However, in a prespecified analysis, meaningful efficacy was observed at Week 24 in a large subset of patients with early-stage disease. Evaluation of the efficacy results is ongoing. An independent data monitoring committee recommended that the study proceed unchanged, based on an assessment of the safety and efficacy data at week 24. According to the protocol, magnetic resonance imaging data will be collected in a subgroup of subjects at week 52 and at additional time points, and radiographs will be taken on all study patients at week 104 and at additional time points. The safety and tolerability data observed in the POSTURE study are consistent with previously reported phase II data in ankylosing spondylitis, as well as six phase III studies of OTEZLA in psoriatic arthritis or psoriasis. No new safety signals were observed. The evaluation of safety and efficacy in the treatment arms is ongoing and the results of the study will be presented at an upcoming medical meeting. These results are from an investigational phase III study. OTEZLA is not approved for the treatment of patients with ankylosing spondylitis in any country.
06:05 EDTDGStocks with implied volatility below IV index mean; DG VLO
Subscribe for More Information
July 8, 2014
18:19 EDTAWAYHomeAway initiated with a Neutral at Macquarie
Subscribe for More Information
14:37 EDTMANUMan U offered over GBP60M a year from Adidas for sponsorship, WSJ says
Subscribe for More Information
08:36 EDTMANUNike ceases sponsorship talks with Manchester United, Bloomberg says
Subscribe for More Information
07:49 EDTCSEU banks on pace to shed record EUR100B on unwanted loans, FT says
Subscribe for More Information
07:32 EDTCSSemiconductor Equipment & Materials International to hold a conference
SEMICON West to be held in San Francisco on July 8-10.
07:07 EDTFIATYFiat founders could tighten hold on firm after Chrysler merge, Reuters says
Subscribe for More Information
06:35 EDTCRZBDCommerzbank expected to pay at least $500M in settlement, NY Times says
Subscribe for More Information
06:33 EDTPAGPPlains All American Pipeline, Plains GP Holdings raises quarterly distribution
Subscribe for More Information
06:25 EDTCRZBDU.S. in settlement talks with Commerzbank, NY Times reports
Subscribe for More Information
06:14 EDTDGStocks with implied volatility below IV index mean; DG CAG
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use